Trastuzumab rezetecan - Jiangsu HengRui Medicine
Alternative Names: SHR-A1811Latest Information Update: 26 Jul 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Fudan University; Henan Cancer Hospital; Jiangsu Hengrui Medicine Co.; Suzhou Suncadia Biopharmaceuticals
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Cell death stimulants; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Oesophageal cancer
- Phase II Biliary cancer; Gynaecological cancer; Salivary gland cancer
- Phase I/II Non-small cell lung cancer; Solid tumours
Most Recent Events
- 04 Jun 2024 Phase-II clinical trials in Biliary cancer (Late-stage disease, Inoperable/Unresectable, Recurrent, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06413745)
- 31 May 2024 Efficacy and adverse events data from a phase II trial in HER2-positive-breast-cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Efficacy and adverse events data from the phase II trial in Salivary gland cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)